Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: Results from the LQ-DMP study.
    
    
        
    
    
        
        Respir. Res. 20:215 (2019)
    
    
    
      
      
	
	    Background: Evidence on the economic impact of chronic obstructive pulmonary disease (COPD) for third-party payers and society based on large real world datasets are still scarce. Therefore, the aim of this study was to estimate the economic impact of COPD severity and its comorbidities, stratified by GOLD grade, on direct and indirect costs for an unselected population enrolled in the structured German Disease Management Program (DMP) for COPD.Methods: All individuals enrolled in the DMP COPD were included in the analysis. Patients were only excluded if they were not insured or not enrolled in the DMP COPD the complete year before the last DMP documentation (at physician visit), had a missing forced expiratory volume in 1 s (FEV1) measurement or other missing values in covariates. The final dataset included 39,307 patients in GOLD grade 1 to 4. We used multiple generalized linear models to analyze the association of COPD severity with direct and indirect costs, while adjusting for sex, age, income, smoking status, body mass index, and comorbidities.Results: More severe COPD was significantly associated with higher healthcare utilization, work absence, and premature retirement. Adjusted annual costs for GOLD grade 1 to 4 amounted to (sic)3809 [(sic)3691-(sic)3935], (sic)4284 [(sic)4176-(sic)4394], (sic)5548 [(sic)5328-(sic)5774], and (sic)8309 [(sic)7583-9065] for direct costs, and (sic)11,784 [(sic)11,257-(sic)12,318], (sic)12, 985 [(sic)12,531-13,443], (sic)15,805 [(sic)15,034-(sic)16,584], and (sic)19,402 [(sic)17,853-(sic)21,017] for indirect costs. Comorbidities had significant additional effects on direct and indirect costs with factors ranging from 1.19 (arthritis) to 1.51 (myocardial infarction) in direct and from 1.16 (myocardial infarction) to 1.27 (cancer) in indirect costs.Conclusion: The findings indicate that more severe GOLD grades in an unselected COPD population enrolled in a structured DMP are associated with tremendous additional direct and indirect costs, with comorbidities significantly increase costs. In direct cost category hospitalization and in indirect cost category premature retirement were the main cost driver. From a societal perspective prevention and interventions focusing on disease control, and slowing down disease progression and strengthening the ability to work would be beneficial in order to realize cost savings in COPD.
	
	
	    
	
       
      
	
	    
		Impact Factor
		Scopus SNIP
		Web of Science
Times Cited
		Scopus
Cited By
		Altmetric
		
	     
	    
	 
       
      
     
    
        Publication type
        Article: Journal article
    
 
    
        Document type
        Scientific Article
    
 
    
        Thesis type
        
    
 
    
        Editors
        
    
    
        Keywords
        Copd ; Dmp ; Healthcare Utilization ; Direct Costs ; Indirect Costs; Obstructive Pulmonary-disease; Care Resource Utilization; Economic Burden; Chronic-bronchitis; Population; Asthma; Trends; Impact
    
 
    
        Keywords plus
        
    
 
    
    
        Language
        english
    
 
    
        Publication Year
        2019
    
 
    
        Prepublished in Year
        
    
 
    
        HGF-reported in Year
        2019
    
 
    
    
        ISSN (print) / ISBN
        1465-9921
    
 
    
        e-ISSN
        1465-993X
    
 
    
        ISBN
        
    
    
        Book Volume Title
        
    
 
    
        Conference Title
        
    
 
	
        Conference Date
        
    
     
	
        Conference Location
        
    
 
	
        Proceedings Title
        
    
 
     
	
    
        Quellenangaben
        
	    Volume: 20,  
	    Issue: 1,  
	    Pages: ,  
	    Article Number: 215 
	    Supplement: ,  
	
    
 
    
        
            Series
            
        
 
        
            Publisher
            BioMed Central
        
 
        
            Publishing Place
            Campus, 4 Crinan St, London N1 9xw, England
        
 
	
        
            Day of Oral Examination
            0000-00-00
        
 
        
            Advisor
            
        
 
        
            Referee
            
        
 
        
            Examiner
            
        
 
        
            Topic
            
        
 
	
        
            University
            
        
 
        
            University place
            
        
 
        
            Faculty
            
        
 
    
        
            Publication date
            0000-00-00
        
 
         
        
            Application date
            0000-00-00
        
 
        
            Patent owner
            
        
 
        
            Further owners
            
        
 
        
            Application country
            
        
 
        
            Patent priority
            
        
 
    
        Reviewing status
        Peer reviewed
    
 
     
    
        POF-Topic(s)
        30202 - Environmental Health
80000 - German Center for Lung Research
    
 
    
        Research field(s)
        Genetics and Epidemiology
    
 
    
        PSP Element(s)
        G-505300-001
G-501800-533
    
 
    
        Grants
        
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2019-10-14